Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer (Q44574462)

4 December 2017

Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer (English)

1 reference

4 December 2017

0 references

Dosia Antonadou

1

1 reference

4 December 2017

Nikolas Throuvalas

2

1 reference

4 December 2017

Aris Petridis

3

1 reference

4 December 2017

Nicolas Bolanos

4

1 reference

4 December 2017

Alexandros Sagriotis

5

1 reference

4 December 2017

Maria Synodinou

6

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 October 2003

1 reference

International Journal of Radiation Oncology Biology Physics

4 December 2017

1 reference

4 December 2017

57

1 reference

4 December 2017

2

1 reference

4 December 2017

402-408

1 reference

4 December 2017

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Innovative treatment strategies in locally advanced and/or unresectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

The current state of paclitaxel and radiation in the combined-modality therapy of non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Optimizing chemoradiation therapy approaches to unresectable stage III non--small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Combined modality therapy for unresectable stage III non-small cell lung cancer: new chemotherapy combinations

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Radiation-induced lung damage: a challenge for radiation biology, experimental and clinical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

The potential role of amifostine in the treatment of non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900590-X

7 January 2021

10.1016/S0360-3016(03)00590-X

Identifiers

DOI

1 reference

release_hy3w3yikezeefkm5tthrpzywim

4 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/hy3w3yikezeefkm5tthrpzywim

24 November 2022

mapped directly with Wikidata item

1 reference